Patient and treatment characteristics
| Patient characteristics . | n (%)* . |
|---|---|
| Total patients, N | 165 |
| TKI maintenance post-HCT | |
| Yes | 97 (59) |
| No | 68 (41) |
| Type of transcript | |
| e1a2 | 88 (53) |
| b2a2 | 22 (13) |
| b3a2 | 11 (7) |
| b3a2 / b2a2 | 20 (12) |
| Other combination | 24 (15) |
| Decade of HCT | |
| 2001-2009 | 73 (44) |
| 2010-2018 | 92 (56) |
| Induction chemotherapy pre-HCT | |
| HCVAD+TKI | 143 (88) |
| Imatinib, n | 70 |
| Dasatinib, n | 49 |
| Investigational TKI, n | 7 |
| Ponatinib, n | 16 |
| Nilotinib, n | 1 |
| Others | 18 (10) |
| Not available | 4 (2) |
| Median age (range), y | 41 (3-70) |
| ≤40 | 82 (49) |
| >40 | 83 (51) |
| Sex | |
| Male | 100 (61) |
| Female | 65 (39) |
| Cytogenetics at diagnosis | |
| Ph alone | 90 (54) |
| Ph plus other cytogenetic abnormalities | 69 (42) |
| Unknown† | 6 (4) |
| HCT-CI score | |
| 0 | 90 (55) |
| 1 | 13 (7) |
| 2 | 24 (15) |
| 3 | 14 (8) |
| >3 | 19 (12) |
| Unknown | 5 (3) |
| Karnofsky score | |
| 100 | 52 (32) |
| 90 | 46 (28) |
| 80 | 38 (23) |
| 70 | 4 (2) |
| Unknown | 25 (15) |
| WBC count at presentation | |
| ≤30 000 | 72 (44) |
| >30 000 | 91 (55) |
| Unknown | 2 (1) |
| Disease status at allo-HCT | |
| CR1 | 116 (70) |
| CR2 | 43 (26) |
| CR3+ | 6 (4) |
| Presence of MSD at HCT | |
| CMR | 81 (49) |
| MMR | 22 (13) |
| No CMR/MMR | 45 (28) |
| Unknown | 17 (10) |
| Transplantation conditioning | |
| Myeloablative | 156 (96) |
| Reduced intensity | 9 (4) |
| GVHD prophylaxis | |
| Tacrolimus/methotrexate±pentostatin±ATG | 137 (83) |
| Cyclophosphamide3/tacrolimus/MMF | 12 (7) |
| Tacrolimus/MMF | 16 (10) |
| Donor type | |
| MSD | 69 (43) |
| MUD | 58 (35) |
| MMUD | 4 (2) |
| Haploidentical | 12 (7) |
| Cord | 22 (13) |
| Stem cell source | |
| Bone marrow | 46 (28) |
| Peripheral blood | 97 (59) |
| Cord blood | 22 (13) |
| Patient characteristics . | n (%)* . |
|---|---|
| Total patients, N | 165 |
| TKI maintenance post-HCT | |
| Yes | 97 (59) |
| No | 68 (41) |
| Type of transcript | |
| e1a2 | 88 (53) |
| b2a2 | 22 (13) |
| b3a2 | 11 (7) |
| b3a2 / b2a2 | 20 (12) |
| Other combination | 24 (15) |
| Decade of HCT | |
| 2001-2009 | 73 (44) |
| 2010-2018 | 92 (56) |
| Induction chemotherapy pre-HCT | |
| HCVAD+TKI | 143 (88) |
| Imatinib, n | 70 |
| Dasatinib, n | 49 |
| Investigational TKI, n | 7 |
| Ponatinib, n | 16 |
| Nilotinib, n | 1 |
| Others | 18 (10) |
| Not available | 4 (2) |
| Median age (range), y | 41 (3-70) |
| ≤40 | 82 (49) |
| >40 | 83 (51) |
| Sex | |
| Male | 100 (61) |
| Female | 65 (39) |
| Cytogenetics at diagnosis | |
| Ph alone | 90 (54) |
| Ph plus other cytogenetic abnormalities | 69 (42) |
| Unknown† | 6 (4) |
| HCT-CI score | |
| 0 | 90 (55) |
| 1 | 13 (7) |
| 2 | 24 (15) |
| 3 | 14 (8) |
| >3 | 19 (12) |
| Unknown | 5 (3) |
| Karnofsky score | |
| 100 | 52 (32) |
| 90 | 46 (28) |
| 80 | 38 (23) |
| 70 | 4 (2) |
| Unknown | 25 (15) |
| WBC count at presentation | |
| ≤30 000 | 72 (44) |
| >30 000 | 91 (55) |
| Unknown | 2 (1) |
| Disease status at allo-HCT | |
| CR1 | 116 (70) |
| CR2 | 43 (26) |
| CR3+ | 6 (4) |
| Presence of MSD at HCT | |
| CMR | 81 (49) |
| MMR | 22 (13) |
| No CMR/MMR | 45 (28) |
| Unknown | 17 (10) |
| Transplantation conditioning | |
| Myeloablative | 156 (96) |
| Reduced intensity | 9 (4) |
| GVHD prophylaxis | |
| Tacrolimus/methotrexate±pentostatin±ATG | 137 (83) |
| Cyclophosphamide3/tacrolimus/MMF | 12 (7) |
| Tacrolimus/MMF | 16 (10) |
| Donor type | |
| MSD | 69 (43) |
| MUD | 58 (35) |
| MMUD | 4 (2) |
| Haploidentical | 12 (7) |
| Cord | 22 (13) |
| Stem cell source | |
| Bone marrow | 46 (28) |
| Peripheral blood | 97 (59) |
| Cord blood | 22 (13) |
ATG, antithymocyte globulin; HCVAD, hyper-CVAD, course A: cyclophosphamide, vincristine, doxorubicin, dexamethasone and course B: methotrexate and cytarabine; MMF, mycophenolate mofetil; MMUD, mismatched unrelated donor; MSD, matched sibling donor; MUD, matched unrelated donor, RT-PCR, reverse-transcription-polymerase chain reaction.
Unless otherwise indicated, the data are number of patients (percentage of total group).
Philadelphia chromosome cytogenetics testing was unavailable at the time of diagnosis, but was detected at a later time in follow-up bone marrow biopsies.